Predictors of orphan drug approval in the European Union

Author： Heemstra Harald  

Publisher： Springer Publishing Company

ISSN： 0031-6970

Source： European Journal of Clinical Pharmacology, Vol.64, Iss.5, 2008-05, pp. : 545-552

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drug Approval Process – In United States of America, European Union and India: A Review

By  

Applied Clinical Research, Clinical Trials and Regulatory Affairs, Vol. 1, Iss. 1, 2014-04 ,pp. : 13-22

Bentham Science Publishers

Access to resources Recommend Favorite

European policies on orphan diseases and drugs stimulate drug development, but could be improved

By  

Drugs & Therapy Perspectives, Vol. 27, Iss. 5, 2011-05 ,pp. : 24-26

Adis International

Access to resources Recommend Favorite

EU orphan drug designations

By  

Inpharma, Vol. 1, Iss. 1521, 2006-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Orphan drug designation in the EU

By  

Inpharma, Vol. 1, Iss. 1578, 2007-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

Pfizer's SU 11248 has been granted orphan drug status by the European Commission

By  

Inpharma, Vol. 1, Iss. 1475, 2005-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite